skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations

Review

(2626) Views  (1491) Full article downloads

Authors: Margarita García, Ana Clopés, Jordi Bruna

Published Date October 2009 Volume 2009:1 Pages 137 - 150
DOI: http://dx.doi.org/10.2147/CMAR.S5598

Margarita García,1 Ana Clopés,2 Jordi Bruna,3 María Martínez,4 Eduard Fort,2 Miguel Gil5

1Clinical Research Unit, Institut Català d’Oncologia-IDIBeLL, L’Hospitalet, Barcelona, Spain; 2Pharmacy Department, Institut Català d’Oncologia-IDIBeLL, L’Hospitalet, Barcelona, Spain; 3Neurology Department and Neuro-Oncology Unit, Hospital Universitario de Bellvitge-IDIBeLL, L’Hospitalet, Barcelona, Spain; 4Oncology Department, Hospital del Mar, Barcelona, Spain; 5Oncology Department and Neuro-Oncology Unit, Institut Català d’Oncologia-IDIBeLL, L’Hospitalet, Barcelona, Spain

Abstract: Chemotherapy is assuming an increasingly important role in the treatment of malignant gliomas, of which temozolomide (TMZ ) is a key part. TMZ belongs to a class of second-generation imidazotetrazinone prodrugs that exhibit linear pharmacokinetics and do not require hepatic metabolism for activation to the active metabolite. New intravenous (iv) TMZ formulations have recently been approved based on studies of bioequivalence between iv and oral TMZ. The efficacy of TMZ was initially evaluated in patients with recurrent disease but phase II and III trials in newly diagnosed gliomas are available. The results of a large phase III trial that compared RT alone vs RT concomitant with oral TMZ created a new standard of adjuvant treatment. Efficacy data for iv TMZ on which its approval was based are those extrapolated from clinical trials with oral TMZ. No comparative data are available on the differences in tolerability and patient satisfaction between oral and iv formulations of TMZ, or for quality of life. New oral formulations could encourage the adherence of patients to treatment. Although patients presumably would prefer oral treatment, iv formulations may be an alternative in noncompliant patients or patients for whom good adherence could not be expected.

Keywords: temozolomide, brain tumors, new formulations, patient considerations, chemotherapy, glioblastoma

 






Readers of this article also read:

Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University